Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsInterest & Investment IncomeNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Mimedx (MDXG) EBITDA (2016 - 2025)

Historic EBITDA for Mimedx (MDXG) over the last 16 years, with Q3 2025 value amounting to $22.2 million.

  • Mimedx's EBITDA rose 9879.95% to $22.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $53.9 million, marking a year-over-year decrease of 1490.52%. This contributed to the annual value of $58.9 million for FY2024, which is 5859.74% up from last year.
  • Mimedx's EBITDA amounted to $22.2 million in Q3 2025, which was up 9879.95% from $12.4 million recorded in Q2 2025.
  • Over the past 5 years, Mimedx's EBITDA peaked at $23.4 million during Q2 2024, and registered a low of -$9.6 million during Q2 2022.
  • Its 5-year average for EBITDA is $6.2 million, with a median of $10.8 million in 2023.
  • Its EBITDA has fluctuated over the past 5 years, first plummeted by 225024.39% in 2022, then soared by 398176.47% in 2024.
  • Mimedx's EBITDA (Quarter) stood at $1.3 million in 2021, then skyrocketed by 780.23% to $11.3 million in 2022, then surged by 36.95% to $15.5 million in 2023, then fell by 28.64% to $11.1 million in 2024, then soared by 100.74% to $22.2 million in 2025.
  • Its EBITDA stands at $22.2 million for Q3 2025, versus $12.4 million for Q2 2025 and $8.3 million for Q1 2025.